Pharmaceutical

XORTX Announces Pricing of US$1.1 Million Registered Direct Offering

CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX…

2 months ago

Avalyn Announces Multiple Presentations at the Pulmonary Fibrosis Foundation (PFF) Summit 2025

Presentations to Highlight Patient Experience Research, AURA-IPF Phase 2 Trial Design for AP02, and Long-Term Safety Data for AP01BOSTON, Oct.…

2 months ago

Soleno Therapeutics to Report Third Quarter 2025 Financial Results on November 4, 2025, at 4:30 PM ET

REDWOOD CITY, Calif., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel…

2 months ago

Ardelyx Announces Four Abstracts Accepted for Poster Presentations at the American Society of Nephrology’s Kidney Week

WALTHAM, Mass., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to…

2 months ago

Mineralys Therapeutics Announces Late-Breaking Presentation of Phase 2 Explore-CKD Trial of Lorundrostat at American Society of Nephrology (ASN) Kidney Week 2025

~ Late-breaking Phase 2 trial data evaluating the safety and efficacy of 25 mg of lorundrostat in participants with hypertension…

2 months ago

AskBio Announces Publication in Nature Medicine of 12-month data from Phase 1 Trial of AB-1002 Gene Therapy in Participants with Congestive Heart Failure

Research Triangle Park, N.C., Oct. 21, 2025 (GLOBE NEWSWIRE) -- First-in-human trial of investigational gene therapy AB-1002 designed to evaluate…

2 months ago

PetVivo Holdings, Inc. Addresses Veterinary Industry’s GEN Z Problem With Breakthrough AI License Agreement

PetVivo Holdings, Inc. New Invite from Dawn's Pet Care MINNEAPOLIS, Oct. 21, 2025 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (OTCQX:…

2 months ago

Plus Therapeutics Updates on CNSide® Diagnostic Platform Launch

Expands commercial readiness and diagnostic, manufacturing footprint Appoints new leadership in commercial strategy and technical operations HOUSTON, Oct. 21, 2025…

2 months ago

Clearmind Medicine Enrolls Last Patient for the First Cohort of its FDA-Approved Phase I/IIa Clinical Trial for Alcohol Use Disorder

Vancouver, Canada, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a…

2 months ago